RET and non-small cell lung carcinoma: We initially considered 2,994 NSCLC patients who underwent molecular testing for common EGFR, ERBB2 (HER2), ALK, ROS1, RET, NTRK1/2/3, MET, KRAS, NRAS, and BRAF gene alterations from August 2020 to May 2022.